Cancer clinical trials in the region Île-de-France
696 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Multiple myeloma
#NCT06561854
#2024-510981-18-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
1 recruiting site
Assistance Publique - Hôpitaux de Paris
Phase 3
Amyloidosis
#NCT06128629
#2023-507220-23-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
5 recruiting sites
Intellia Therapeutics
Phase 3
Amyloidosis
#NCT06563895
#2024-513547-82-00
Required histologic types
Other
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required organ involvement status
Absence
5 recruiting sites
Eidos Therapeutics, a BridgeBio company
Phase 3
Amyloidosis
#NCT07052903
#2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Amyloidosis
#NCT07223203
#2025-522544-40-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Neurological
3 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Thyroid and adrenal gland cancer
#NCT04290663
#2024-514603-34-00
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3
Head and neck cancer
#NCT07264075
#2025-522996-27-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
6 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)
Phase 3
Thyroid and adrenal gland cancer
#NCT03583710
Required histologic types
Adrenal gland cancer
Required histologic sub types
Adrenocortical carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
Mitotane
10 recruiting sites
M.D. Anderson Cancer Center
Phase 3
Stomach and esophageal cancer
#NCT06768164
Required histologic types
Stomach
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
2 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.